SCHEDULE: TCG Crossover Updates Stake in ALX Oncology Holdings
Beneficial Ownership Filing Amendment
TCG Crossover entities and Chen Yu have amended their Schedule 13G filing to reflect updated beneficial ownership of ALX Oncology Holdings Inc. common stock.
Summary
- This filing is an amendment (Amendment No. 1) to a previously filed Schedule 13G, updating beneficial ownership information for ALX Oncology Holdings Inc.
- The reporting persons include TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu.
- The total beneficial ownership reported by Chen Yu is 5,655,487 shares, representing 4.2% of the class.
- This ownership is comprised of 2,827,739 shares held by TCG Crossover II and 2,827,748 shares held by TCG Crossover III.
- The filing states that TCG Crossover GP II and TCG Crossover GP III are general partners of their respective funds and may be deemed to have voting, investment, and dispositive power.
- Chen Yu is the sole managing member of both TCG Crossover GP II and TCG Crossover GP III and may be deemed to share voting, investment, and dispositive power.
- The total number of outstanding shares of Common Stock as of May 1, 2026, was reported by the Issuer as 134,562,917.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, primarily an amendment to a previous filing that updates beneficial ownership information without new strategic or financial disclosures.
Future Outlook
This filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire a significant stake in a public company. This amendment indicates a change or update in the beneficial ownership held by TCG Crossover entities and Chen Yu in ALX Oncology Holdings, a biotechnology company.
Stakeholder Impact
- Shareholders may note the updated ownership stake by TCG Crossover and Chen Yu, which could influence market perception of institutional interest in ALX Oncology Holdings.
Key Dates
| Date | Description |
|---|---|
| 02/06/2026 | Original Schedule 13G filing date. |
| 05/01/2026 | Date as of which the Issuer reported outstanding shares. |
| 05/08/2026 | Date the Issuer's Quarterly Report on Form 10-Q was filed. |
| 06/30/2026 | Date of the event requiring this filing (Amendment No. 1). |
| 08/14/2026 | Date of certification and signature for Amendment No. 1. |
Keywords
ALX Oncology Holdings, Schedule 13G, Beneficial Ownership, TCG Crossover, Chen Yu, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.